0001493152-21-020615.txt : 20210819 0001493152-21-020615.hdr.sgml : 20210819 20210818192209 ACCESSION NUMBER: 0001493152-21-020615 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210817 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210819 DATE AS OF CHANGE: 20210818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagenic Therapeutics, Inc.\new CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12555 FILM NUMBER: 211187963 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Atrinsic, Inc. DATE OF NAME CHANGE: 20090630 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 17, 2021

PROTAGENIC THERAPEUTICS, INC.

(Exact name of Company as specified in its charter)

Delaware		000-51353		06-1390025
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

149 Fifth Avenue, Suite 500, New York, NY		10010
(Address of principal executive offices)		(Zip Code)

212-994-8200

(Company’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Protagenic Therapeutics, Inc. Common Stock		PTIX		Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants		PTIXW		Nasdaq

Item 7.01. Regulation FD.

The company’s press release announcing Second Quarter 2021 results and providing a business update, which also included changes in the timeline of initiation of the clinical trial of its lead drug candidate, PT00114, is furnished hereto as Exhibit 99.1.

The information in this Form 8-K (including the Exhibit) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referenced in such a filing.

Item 8.01. Other Events.

As previously announced, upon review of the company’s investigational new drug (IND) application filed on June 29, 2021, the U.S. Food and Drug Administration (FDA) requested that the company provide clinical sites with ready-to-inject clinical vials rather than providing site pharmacies with the drug substance to be formulated locally. Following the FDA’s request, the company immediately began implementing this required change. As a result of this development, the company has revised its anticipated upcoming milestones as outlined in its 2Q 2021 earnings release, issued yesterday:

Q4 2021: Re-filing of IND application for PT00114

Q1 2022: Initiation of Phase I/IIa study for PT00114

1H 2022: Initial Data Readout of Phase I/IIa study

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description

99.1		Press release – “Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update”

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTAGENIC THERAPEUTICS, INC.

Date: August 18, 2021	By:	/s/ Alexander K. Arrow
	Name:	Alexander K. Arrow
	Title:	Chief Financial Officer

3

EX-99.1 2 ex99-1.htm

Exhibit 99.1

FOR IMMEDIATE RELEASE

Protagenic Therapeutics Announces Second Quarter 2021 Results and

Provides Business Update

August 17, 2021 — NEW YORK — Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June 30, 2021.

Recent Highlights

	●	Received FDA guidance to provide clinical sites with ready-to-inject clinical vials of PT00114 as part of its IND filing
	●	Hosted a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction
	●	Closed a $13.2 million public offering
	●	Uplisted to the Nasdaq Capital Market

“During the second quarter and year to date, we made substantial progress towards advancing PT00114 into the clinic, in order to treat stress-related neuropsychiatric disorders which afflict millions, and represents a $20 billion addressable market,” said Dr. Garo Armen, CEO of Protagenic Therapeutics. “We have a clear clinical path toward major indications. We anticipate rapid, objective efficacy and safety readouts in the coming quarters. As we execute against those stated milestones, we expect to drive significant shareholder value.”

Anticipated Upcoming Milestones

	●	Q4 2021: Re-filing of IND application for PT00114
	●	Jan 2022: Initiation of Phase I/IIa study for PT00114
	●	1H 2022: Initial Data Readout of Phase I/IIa study
	●	Q3 2022: Final Readout of Phase I/IIa study

Financial Results for the Second Quarter Ended June 30, 2021:

	●	Net loss attributable to common stockholders for the quarter ended June 30, 2021 was approximately $2.6 million, compared to approximately $0.6 million for the quarter ended June 30, 2020.
	●	Research and development expense totaled approximately $0.1 million for the quarter ended June 30, 2021, compared to approximately $0.1 million during the quarter ended June 30, 2020.
	●	General and administrative expense was approximately $2.2 million for the quarter ended June 30, 2021, compared to approximately $0.4 million during the quarter ended June 30, 2020.

	●	On April 29, 2021, the company closed on an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit. Each unit was comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant was exercisable at a price of $4.98 per share and will expire five years from issuance. The common stock and warrants comprising the units separated upon closing of the offering and were issued separately.
	●	As of June 30, 2021, the Company had cash and cash equivalents of approximately $11.9 million.
	●	As of August 16, 2021, the Company had approximately 16.6 million common shares outstanding.

About Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat several stress related disorders. For more information, visit http://www.protagenic.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Protagenic Therapeutics’ product candidates and pre-clinical development and clinical trial plans and activities. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the pre-clinical testing and eventual clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in pre-clinical and clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors described under the Risk Factors section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.. Protagenic Therapeutics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Protagenic undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Analyst Contact:

Alexander K. Arrow, MD, CFA

Chief Financial Officer

213-260-4342

alex.arrow@protagenic.com

Media Contact:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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ptix-20210817.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 ptix-20210817_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 ptix-20210817_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Protagenic Therapeutics, Inc. Common Stock Protagenic Therapeutics, Inc. Common Stock Warrants Statement [Table] Affiliate, Collateralized Security [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ptix-20210817_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001022899 2021-08-17 2021-08-17 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2021-08-17 2021-08-17 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2021-08-17 2021-08-17 iso4217:USD shares iso4217:USD shares 0001022899 false Protagenic Therapeutics, Inc.\new 8-K 2021-08-17 DE 000-51353 06-1390025 149 Fifth Avenue Suite 500 New York NY 10010 212 994-8200 false false false false Protagenic Therapeutics, Inc. Common Stock PTIX NASDAQ Protagenic Therapeutics, Inc. Common Stock Warrants PTIXW NASDAQ XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 17, 2021
Affiliate, Collateralized Security [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 17, 2021
Entity File Number	000-51353
Entity Registrant Name	Protagenic Therapeutics, Inc.\new
Entity Central Index Key	0001022899
Entity Tax Identification Number	06-1390025
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	149 Fifth Avenue
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	212
Local Phone Number	994-8200
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Protagenic Therapeutics, Inc. Common Stock
Affiliate, Collateralized Security [Line Items]
Title of 12(b) Security	Protagenic Therapeutics, Inc. Common Stock
Trading Symbol	PTIX
Security Exchange Name	NASDAQ
Protagenic Therapeutics, Inc. Common Stock Warrants
Affiliate, Collateralized Security [Line Items]
Title of 12(b) Security	Protagenic Therapeutics, Inc. Common Stock Warrants
Trading Symbol	PTIXW
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://protagenic.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ptix-20210817.xsd ptix-20210817_def.xml ptix-20210817_lab.xml ptix-20210817_pre.xml http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "ptix-20210817_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ptix-20210817_lab.xml" ] }, "presentationLink": { "local": [ "ptix-20210817_pre.xml" ] }, "schema": { "local": [ "ptix-20210817.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 2, "memberStandard": 0, "nsprefix": "PTIX", "nsuri": "http://protagenic.com/20210817", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-08-17to2021-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://protagenic.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-08-17to2021-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "PTIX_ProtagenicTherapeuticsInc.CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Protagenic Therapeutics, Inc. Common Stock" } } }, "localname": "ProtagenicTherapeuticsInc.CommonStockMember", "nsuri": "http://protagenic.com/20210817", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "domainItemType" }, "PTIX_ProtagenicTherapeuticsInc.CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Protagenic Therapeutics, Inc. Common Stock Warrants" } } }, "localname": "ProtagenicTherapeuticsInc.CommonStockWarrantsMember", "nsuri": "http://protagenic.com/20210817", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_AffiliateCollateralizedSecurityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Affiliate, Collateralized Security [Line Items]" } } }, "localname": "AffiliateCollateralizedSecurityLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001493152-21-020615-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-020615-xbrl.zip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end